Articles tagged with: Pomalidomide

News»

[ by | Jun 3, 2012 4:59 pm | 14 Comments ]
ASCO 2012 Multiple Myeloma Update – Day Three: Carfilzomib And Pomalidomide

Results from many important multiple myeloma studies were presented this morning during the third day of the American Society of Clinical Oncology (ASCO) annual meeting.  Most of the talks were about potential new anti-myeloma drugs.

This update will summarize the presentations about carfilzomib (Kyprolis) and pomalidomide (Pomalyst), two of the most promising new treatments being developed for multiple myeloma.  Both of these drugs have been submitted to the U.S. Food and Drug Administration for potential approval as new myeloma treatments.

Carfilzomib

The first three presentations were …

Read the full story »

News»

[ by | Jun 2, 2012 4:47 pm | 2 Comments ]
ASCO 2012 Multiple Myeloma Update – Day Two: Poster Session

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began yesterday and goes through Tuesday.

The first of the myeloma-related sessions at this year's meeting began this morning with a poster session, in which important new research findings were summarized on posters throughout a large conference hall.

MLN9708

This morning’s session included two posters about MLN9708 (ixazomib), an oral drug that works similarly to Velcade (bortezomib) and is being investigated for the treatment of multiple myeloma as …

Read the full story »

News»

[ by | May 16, 2012 1:53 pm | 7 Comments ]
Myeloma Research To Be Presented At The American Society of Clinical Oncology’s 48th Annual Meeting (ASCO 2012)

The 48th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 1, through Tuesday, June 5, in Chicago.

More than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Collaborating to Conquer Cancer.”

The meeting will include many presentations and seminars focused specifically on multiple myeloma. The ASCO website currently lists nearly 50 myeloma-based presentations (included under “lymphoma and plasma cell …

Read the full story »

News»

[ by | Apr 26, 2012 7:18 am | 4 Comments ]
Celgene Submits Pomalidomide For FDA Approval

Celgene Corporation announced this morning that it has completed submission of its application to the U.S. Food and Drug Administration (FDA) for the approval of pomalidomide as a treatment for relapsed and refractory multiple myeloma.

If the FDA approves pomalidomide based on this application, Celgene could begin marketing pomalidomide in the United States as early as this fall.

Pomalidomide (Pomalyst), which belongs to the same class of drugs as thalidomide (Thalomid) and Revlimid (lenalidomide), is being developed by Celgene (NASDAQ: CELG) for the treatment of multiple myeloma and myelofibrosis. …

Read the full story »

NewsFlash »

[ by | Apr 23, 2012 10:21 am | Comments Off ]

Progression From MGUS To Myeloma Is Similar Among Japanese And Westerners – A recent study found that Japanese people with monoclonal gammopathy of undetermined significance (MGUS) progressed to multiple myeloma at rates similar to those previously reported for Westerners.  Specifically, the results showed that 3 percent progressed within 5 years, 9 percent within 10 years, 11.4 percent within 15 years, and 32.1 percent within 20 years.  For more information, see the study in the journal Rinsho Ketsueki (abstract).

Pomalidomide May Be Effective In Patients With Amyloidosis – Results from a Phase 2 study show that pomalidomide plus dexamethasone (Decadron), a combination being studied for the treatment of multiple myeloma, may also be effective in previously treated patients with immunoglobulin light chain amyloidosis.  Amyloidosis is a blood disorder that results in the abnormal accumulation of proteins in tissues and organs throughout the body.  An estimated 10 percent to 15 percent of myeloma patients also develop symptoms associated with amyloidosis (see related Beacon news).  Among the 33 amyloidosis patients included in the study, 48 percent had improved blood cell counts and 15 percent had organ improvement after treatment with pomalidomide and dexamethasone.  The median progression-free survival was 14 months, and the median overall survival was 28 months.  For more information, see the study in the journal Blood (abstract).

Participants Needed For Myeloma Risk Association Study – The International Myeloma Foundation is conducting a study to determine why certain races and family members are at an increased risk of developing multiple myeloma.  The study is a brief survey that multiple myeloma patients can complete via the Internet.  To participate, see the study website.

Clinical Insights Education Program – The Multiple Myeloma Research Foundation (MMRF) is sponsoring an education program for myeloma patients and their families about multiple myeloma clinical insights. The event will be held on April 27 in New York City. Myeloma experts from leading cancer centers will speak about the latest advances in frontline therapy, stem cell transplants, relapsed and refractory myeloma, supportive care, and clinical trials. A question and answer session is included in the program. Registration will begin at 9 a.m., and the program will conclude at 2:30 p.m. For more information or to register, please see the MMRF website.

For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.